<p>Clearside Biomedical (CLSD) 的股票在週一暴跌，此前這家生物製藥公司宣佈自願申請第 11 章破產。公司表示，其董事會在評估所有戰略選項後做出了申請破產的決定。</p>
<h3>TipRanks 黑色星期五促銷</h3>
<ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取您投資所需的數據支持洞察和研究工具。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
<p>Clearside Biomedical 打算在破產過程中出售其全部或部分資產。這將要求有意向的各方提交對其資產或業務的有約束力的報價。Clearside Biomedical 指出，這將不受任何留置權和權益的限制。公司還向破產法院申請在此期間繼續正常運營的許可。</p>
<p>Clearside Biomedical 的總裁兼首席執行官 George Lasezkay 表示：&#34;我們相信，基於我們經過臨牀驗證的 SCS 微注射器平台及相關知識產權、成功的脈絡膜上 CLS-AX（阿西替尼注射懸液）臨牀開發項目、多項脈絡膜上許可協議及其他相關資產，我們擁有有吸引力的資產。&#34;</p>
<h2><strong>Clearside Biomedical 今日股票走勢</strong></h2>
<p>Clearside Biomedical 的股票在週一的盤前交易中下跌了 70.59%，此前在週五上漲了 4.21%。截至目前，該股年初至今已下跌 80.91%，過去 12 個月下跌 83.21%。</p>
<p>隨着今天破產消息的發佈，CLSD 股票交易活躍。截至撰寫時，交易量超過 774,000 股，而三個月的日均交易量約為 64,390 股。</p>

Clearside生物醫學

CLSDQ

<p>Clearside Biomedical (CLSD) 的股票在公司宣佈自願申請第 11 章破產後大幅下跌。董事會在評估戰略選項後做出了這一決定。Clearside 計劃在破產過程中出售其資產，並已請求繼續運營。該股票在盤前交易中下跌了 70.59%，並且交易活動非常活躍</p>

<p>Clearside Biomedical (CLSD) stock plummeted on Monday after the biopharmaceutical company announced its voluntary filing for Chapter 11 bankruptcy. The company said its Board of Directors made the decision to file for bankruptcy after having evaluated all strategic options.</p>
<div class="lb-trans"><p>Clearside Biomedical (CLSD) 的股票在週一暴跌，此前這家生物製藥公司宣佈自願申請第 11 章破產。公司表示，其董事會在評估所有戰略選項後做出了申請破產的決定。</p>
</div><h3>TipRanks Black Friday Sale</h3>
<div class="lb-trans"><h3>TipRanks 黑色星期五促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取您投資所需的數據支持洞察和研究工具。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
</div><p>Clearside Biomedical intends to pursue the sale of all or part of its assets during the bankruptcy process. This will require interested parties to submit binding offers for its assets or business. Clearside Biomedical notes this would be free and clear of liens and interests. The company has also sought permission from the bankruptcy court to continue normal operations during this period.</p>
<div class="lb-trans"><p>Clearside Biomedical 打算在破產過程中出售其全部或部分資產。這將要求有意向的各方提交對其資產或業務的有約束力的報價。Clearside Biomedical 指出，這將不受任何留置權和權益的限制。公司還向破產法院申請在此期間繼續正常運營的許可。</p>
</div><p>George Lasezkay, President and CEO of Clearside Biomedical, said, &#34;We believe that we have attractive assets based on our clinically proven SCS Microinjector platform and associated intellectual property, our successful suprachoroidal CLS-AX (axitinib injectable suspension) clinical development program, multiple suprachoroidal licensing agreements and other related assets.&#34;</p>
<div class="lb-trans"><p>Clearside Biomedical 的總裁兼首席執行官 George Lasezkay 表示：&#34;我們相信，基於我們經過臨牀驗證的 SCS 微注射器平台及相關知識產權、成功的脈絡膜上 CLS-AX（阿西替尼注射懸液）臨牀開發項目、多項脈絡膜上許可協議及其他相關資產，我們擁有有吸引力的資產。&#34;</p>
</div><h2><strong>Clearside Biomedical Stock Movement Today</strong></h2>
<div class="lb-trans"><h2><strong>Clearside Biomedical 今日股票走勢</strong></h2>
</div><p>Clearside Biomedical stock was down 70.59% in pre-market trading on Monday, following a 4.21% rally on Friday. The shares have decreased 80.91% year-to-date and 83.21% over the past 12 months.</p>
<div class="lb-trans"><p>Clearside Biomedical 的股票在週一的盤前交易中下跌了 70.59%，此前在週五上漲了 4.21%。截至目前，該股年初至今已下跌 80.91%，過去 12 個月下跌 83.21%。</p>
</div><p>With today's bankruptcy news came heavy trading of CLSD stock. This saw more than 774,000 shares traded as of this writing, compared to a three-month daily average of about 64,390 units.</p>
<div class="lb-trans"><p>隨着今天破產消息的發佈，CLSD 股票交易活躍。截至撰寫時，交易量超過 774,000 股，而三個月的日均交易量約為 64,390 股。</p>
</div>

Clearside 生物醫學的股票（CLSD）今天為何下跌？